Allogene Therapeutics Closes $200.4M Public Offering

Allogene Therapeutics announced the closing of its underwritten public offering, which included the partial exercise of the underwriters' option. The company sold a total of 100,200,000 shares of common stock at $2.00 per share. This offering generated aggregate gross proceeds of $200.4 million, which Allogene intends to use for general corporate purposes, including clinical trials, research and development, and administrative expenses.